Core Facilities

Genetic Modeling Centre

  • The BC Cancer Center for Genetic Modeling (CGM) was initiated in 2004 as an expansion of the Terry Fox Laboratory Transgenics Core after a decade of successful operations.  It is situated within the BC Cancer Research Center (BCCRC) building, which houses a 1,995 m2 rodent facility (ARC) that provides a barrier environment matching the highest standards of pathogen control for commercial facilities around the world.  A biohazard Containment Level III facility, an Embryonic Stem (ES) cell lab, and mouse phenotyping suites also exist as infrastructure support for the CGM.

    The CGM has state of the art capabilities for generating mouse mutant models through ES cell gene targeting and pronuclear microinjection of mouse zygotes.  In addition the CGM provides services for cryo-preservation and mouse re-derivation, and has an ES cell core that can derive and manipulate various strains of ES cells.  The CGM also has a mandate to develop or bring in new platform technologies to make the generation of mouse mutants quicker and easier as well as to develop technologies to further facilitate mouse embryo manipulations.

    The CGM can provide the following on a fee-for-service basis
    • Pronuclear injections into mouse zygotes
    • Blastocyst injections with any strain of ES cells
    • Gene targeting into ES cells
    • CRISPR/Cas9 gene editing in ES cells, zygotes
    • Embryonic Stem Cell (ESC) derivation
    • ESC culture
    • Mouse Embryonic Fibroblast production (MEF)
    • Cre- and Flp-mediated recombination
    • Mouse strain rederivation (fresh or frozen embryos)
    • in-vitro fertilization (fresh or frozen sperm)
    • Cryopreservation of mouse strains (sperm or embryo)
    • Embryo harvest at various stages of development
    • Timed matings
    • Superovulation
    • Surgical services


    Under Development
    • CRISPR/Cas9 gene editing using 2-cell injection in mouse embryos


    Milestones for 2018
    • CRISPR/Cas9 gene editing using various methods:  zygote injection, electroporation, and we have just started injecting into 2-cell embryos.
    • A Tead2 knockout mouse was successfully created using CRISPR/Cas9 in mouse embryos


    Recent Publications

    Xiang P, Wei W, Hofs N, Clemans-Gibbon J, Maetzig T, Lai CK, Dhillon I, May C, Ruschmann J, Schneider E, Rosten P, Hu K, Kuchenbauer F, Hoodless PA, Humphries RK. (2017). A knock-in mouse strain facilitates dynamic tracking and enrichment of MEIS1. Blood Advances 1:2225-2235. Doi:10.1182/bloodadvances.2017010355.



  • Nicole Hofs

    Assistant Manager, Transgenic Core